Rigel Pharmaceuticals Inc

NASDAQ:RIGLUnited States

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Contact Information

Headquarters

611 GATEWAY BOULEVARD, SUITE 900SOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-624-1100

Fax

650-624-1101

Executives

Independent Chairman of the Board

Gregg Lapointe

President, Chief Executive Officer, Director

Raul Rodriguez

Chief Financial Officer, Executive Vice President

Dean Schorno

Executive Vice President, General Counsel, Company Secretary

Raymond Furey

Executive Vice President, Chief Medical Officer

Lisa Rojkjaer